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What is the best regimen 
for newly diagnosed
hypertension?
■ EVIDENCE-BASED ANSWER
Low-dose thiazide diuretics (eg, hydrochloroth-
iazide 12.5 to 25 mg/d) are the best first-line phar-
macotherapy for treating uncomplicated hyperten-
sion (strength of recommendation [SOR]: A, based
on randomized trials [RCTs] and 1 meta-analysis).
Alternate first-line agents include angiotensin-
converting enzyme (ACE) inhibitors, beta 
blockers, and calcium channel blockers (SOR: A,
based on RCTs).
■ EVIDENCE SUMMARY
Three landmark placebo-controlled studies have
established that thiazide diuretic–based treat-
ment reduces morbidity and mortality among
patients with hypertension.1–3 Based on these
data, thiazide diuretic therapy is considered 
the gold-standard treatment for uncomplicated 
hypertension.
Several other clinical trials have subsequently
compared the effect of thiazide diuretics with
that of other antihypertensive agents (beta-block-
ers, calcium channel blockers, and alpha-block-
ers) on patient-oriented outcomes. These were
analyzed in a recent meta-analysis of 42 clinical
trials that included 192,478 patients randomized
to 7 treatment strategies including placebo.4
Results from the largest antihypertensive clinical
trial, the Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALL-
HAT), were included in this meta-analysis.5
Comparative results are depicted in the Table.
Although these data showed no differences
between drug therapies in total and cardiovascu-
lar disease mortality, low-dose diuretics reduced
certain cardio-vascular endpoints (ie, heart fail-
ure, stroke, cardiovascular disease events) more
than other drug therapies. 
Angiotensin receptor blockers (ARBs) have
not been compared with thiazide diuretics in a
trial. Two long-term trials have compared an ARB
to other types of drug therapy: losartan vs
atenolol in the Losartan Intervention for
Endpoint Reduction (LIFE) trial,6 and valsartan
vs amlodipine in the Valsartan Antihypertensive
Long-term Use Evaluation (VALUE) trial.7 In the
LIFE trial, the primary composite endpoint of car-
diovascular death, myocardial infarction, and
stroke was less with losartan than atenolol (23.8
vs 27.9 events per 1000 patient-years, losartan
and atenolol, respectively; number needed to
treat=243 people-years, P=.021).6 However, in
the VALUE trial, the primary endpoint of time to
cardiac event was not different between valsar-
tan and amlodipine (25.5 vs 24.7 events per 1000
patient-years, valsartan and amlodipine, respec-
tively; P=.49).7
■ RECOMMENDATIONS FROM OTHERS
The Seventh Report of the Joint National
Committee (JNC7) recommended thiazide diuret-
ics as preferred initial agents in uncomplicated
hypertension.8 The European Society of Hyper-
tension/European Society Cardiology recom-
mended either a diuretic, beta-blocker, calcium
channel blocker, ACE inhibitor, or ARB for initial
therapy stating that blood pressure control to rec-
ommended values via any agent is more impor-
tant than the type of agent used.9 Both guidelines
identified other antihypertensives that may be
used in addition to or in place of thiazide diuret-
ics for compelling indications, such as heart fail-
ure, diabetes, high-risk cardiovascular disease,
chronic kidney disease, post-myocardial infarc-
tion, and secondary stroke prevention.
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First-line treatments for hypertension
Relative risk (95% CI) of outcome
Low-dose CVD Total
diuretic vs CHD CHF Stroke CVD events mortality mortality
Beta-blocker 0.87 0.83 0.90 0.89* 0.93 0.99
(0.74–1.03) (0.68–1.01) (0.76–1.06) (0.80–0.98) (0.81–1.07) (0.91–1.07)
ACE inhibitor 1.00 0.88* 0.86* 0.94 0.93 1.00 
(0.88–1.14) (0.80–0.96) (0.77–0.97) (0.89–1.00) (0.85–1.02) (0.95–1.05)
Calcium 0.89 0.74* 1.02 0.94 0.95 1.03 
channel blocker (0.76–1.01) (0.67–0.81) (0.91–1.14) (0.89–1.00) (0.87–1.04) (0.98–1.08)
Alpha-blocker 0.99 0.51* 0.85 0.84* 1.00 0.98 
(0.75–1.31) (0.43–0.60) (0.66–1.10) (0.75–0.93) (0.75–1.34) (0.88–1.10)
*Denotes statistically significant difference favoring low-dose diuretics (P<.05).
CI, confidence interval; CHD, congestive heart disease; CVD, cardiovascular disease; ACE, angiotensin-converting enzyme.
Source: Psaty BM, Lumley T, Furberg CD, et al, JAMA 2003.4
TA B L E
■ CLINICAL COMMENTARY
Thiazide diuretics: first or second agent
for patients with hypertension
Skeptics argue that other antihypertensives are
equal to thiazides. However, thiazides are the
least expensive agents (1-year hydrochloroth-
iazide 25 mg/d is <$25.00). This aspect of thera-
py supports thiazides as first-line pharmacother-
apy. The debate of which agent to use first may
be moot considering most hypertensive patients
require 2 or more drugs to achieve a systolic
blood pressure goal of <140 mm Hg. In addition,
the JNC7 recommended starting with 2 agents for
patients far from their blood pressure goal (eg,
systolic blood pressure ≥160 mm Hg). Therefore,
even if a thiazide is not the initial agent (because
of preference or other compelling indications) it
should be the second agent for most patients. 
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